"L&G Pharma Breakthrough UCITS ETF" is an exchange-traded investment fund (ETF). It refers to the Solactive Biotechnology Breakthrough Value Index. This index reflects the development of stocks . The ETF replicates its index using full physical replication, so it contains all the securities of its reference index. The ETF's earnings (dividends) are automatically reinvested (accumulated). The fund company L&G ETF claims a total expense ratio (TER) of 0.49% per year. The yearly average divergence from the index performance (Tracking Difference) since 2019 was 0.70% per year. Therefore, the ETF was more expensive than the TER suggests.